|Systematic (IUPAC) name|
|Pregnancy cat.||Not classified (US)|
|Legal status||Not approved for use or sale: US; prescription medicine (POM): India, Australia, Canada, Israel; Over the Counter (OTC): UK (Pharmacy only), Belgium, Egypt, Ireland, Italy, Japan, Netherlands, South Africa, Switzerland, China, Russia, Slovakia, Thailand, Malta, South Korea, and Romania|
|Routes||Oral, intravenous, rectal|
|Metabolism||Hepatic and intestinal (first-pass)|
|Excretion||Breast milk, renal|
|ATC code||A03 QP51|
|Mol. mass||425.911 g/mol|
|(what is this?)|
Domperidone (trade names Motilium, Motillium, Motinorm Costi, Nomit and Molax) is a medication developed by Janssen Pharmaceutica that is a peripheral, specific blocker of dopamine receptors. It is administered orally, rectally, or intravenously. Domperidone is given in order to relieve nausea and vomiting; to increase the transit of food through the stomach (as a prokinetic agent through increase in gastrointestinal peristalsis); and to increase lactation (breast milk production) by release of prolactin. It is also used in the scientific study of the way dopamine (an important neurotransmitter) acts in the body.
- 1 Mechanism of Action
- 2 Uses
- 3 Adverse effects
- 4 Interactions
- 5 Contraindications
- 6 History
- 7 Brand names and formulations by nation
- 8 See also
- 9 References
- 10 External links
Mechanism of Action
Domperidone is a peripheral dopamine (D2) and (D3) receptor antagonist. It provides relief from nausea by blocking receptors at the chemo-receptor trigger zone (a location in the nervous system that registers nausea) at the floor of the fourth ventricle (a location near the brain). It increases motility in the upper gastrointestinal tract to a moderate degree and lowers esophageal sphincter pressure by blocking dopamine receptors in the gastric antrum and the duodenum. It blocks dopamine receptors in the posterior pituitary gland increasing release of prolactin which in turn increases lactation. Domperidone may be more useful in some patients and cause harm in others by way of the genetic characteristic of the person, such as polymorphisms in the drug transporter gene ABCB1, the potassium channel KCNH2 gene, and α1D--adrenoceptor ADRA1D gene.
The uses or indications of domperidone vary between nations. For instance, in Italy it is used in the treatment of gastroesophageal reflux disease and in Canada, the drug is indicated in upper gastrointestinal motility disorders and to prevent gastrointestinal symptoms associated with the use of dopamine agonist antiparkinsonian agents. In the United States domperidone's use is not approved.
Nausea and vomiting
Gastroparesis is a medical condition characterised by delayed emptying of the stomach when there is no mechanical gastric outlet obstruction. Its cause is most commonly idiopathic, a diabetic complication or a result of abdominal surgery. The condition causes nausea, vomiting, fullness after eating, early satiety (feeling full before the meal is finished), abdominal pain and bloating.
However, increased rate of gastric emptying induced by drugs like domperidone does not always correlate (equate) well with relief of symptoms.
Parkinson's disease is a chronic neurological condition where a decrease in dopamine in the brain leads to rigidity (stiffness of movement), tremor and other symptoms and signs. Poor gastrointestinal function, nausea and vomiting is a major problem for people with Parkinson's disease because most medications used to treat Parkinson's disease are given by mouth. These medications, such as levodopa can cause nausea as a side effect. Furthermore, anti-nausea drugs, such as metoclopramide, which do cross the blood brain barrier may worsen the extra-pyramidal symptoms of Parkinson's disease.
Domperidone can be used to relieve gastrointestinal symptoms in Parkinson's disease, because, even though it blocks dopamine receptors (which would be expected to worse Parkinson's disease), it does not cross the blood brain barrier (the barrier between the blood circulation of the brain and the rest of the body). In addition to this, domperidone may enhance the bioavailability (effect) of levodopa (one of the main treatments in Parkinson's disease.)
Although these features make domperidone a useful drug in Parkinson's disease, caution is needed due to the cardiotoxic side effects of domperidone when given intravenously, in elderly people and in high doses (> 30mg per day). A clinical sign of domperidone's potential toxicity to the heart is the prolongation (lengthening) of the QT interval (a segment of the heart's electrical pattern).
The hormone prolactin stimulates lactation (production of breast milk). Dopamine, released by the hypothalamus stops the release of prolactin from the pituitary gland. Domperidone, by acting as an anti-dopaminergic agent, results in increased prolactin secretion, and thus promotes lactation (that is, it is a galactogogue). In some nations, including Australia domperidone is used off label, based on anectdotal evidence of its usefulness, as a therapy for mothers who are having difficulty breastfeeding with uncertain result. In the United States, domperidone is not approved for this or any other use. A study called the EMPOWER trial has been designed to assess the effectiveness and safety of domperidone in assisting mothers of preterm babies to supply breast milk for their infants.
Penetration of immature blood brain barrier
In Britain a legal case involved the death of two children of a mother whose three children had all had hypernatraemia. She was charged with poisoning the children with salt. One of the children, who was born at 28 weeks gestation with respiratory complications and had had a fundoplication for gastroesophageal reflux and failure to thrive was prescribed domperidone. An advocate for the mother suggested the child may have suffered neurolept malignant syndrome as a side effect of domperidone due to the drug crossing the child's immature blood brain barrier.
Erythromycin and other macrolide antibiotics inhibit the metabolism of domperidone (in-vitro) thus increasing the concentration of domperidone and potential side effects of the drug. This is of concern as both drugs may be used to treat gastroparesis.
- Prolactin secreting pituitary tumor.
- Triazole antifungal medications such as ketoconazole, itraconazole, fluconazole.
- Macrolide antibiotics such as erythromycin and clarithromycin.
- Potent CYP3A4 inhibitors.
- Mechanical bowel disorders such as bowel obstruction, gastrointestinal haemorrhage or bowel perforation
- Moderate hepatic impairment (liver disease).
Janssen Pharmaceutical has brought domperidone before the United States Federal drug administration (FDA) several times, including in the 1990s.
Brand names and formulations by nation
|Australia||Janssen - Cilag||Motilium||10 mg scored tablet.|
|Belgium and the Netherlands||-||Motilium||Form 2013 only by prescription in Belgium.|
|Belgium||Sanofi - Aventis||Primperan||-|
|Canada||-||Motilium (1985 - 2002)||Generic brands available.|
|India||Salius Pharma||Escacid DXR||pantoprazole 40 mg and domperidone SR 30mg|
|India||Medley pharmaceuticals||Dompan||pantoprazole 40mg and domperidone 10mg|
|India||Rhubarb pharmaceuticals||-||domperidone 5,10 and 20 mg tablets.|
|India||Ipca Laboratories, Mumbai||Domperi suspension||domperidone 1 mg/ml, 30 ml suspension.|
|India||Torrent pharmaceuticals||Domstal||- |
|India||Ozone pharmaceuticals and chemicals||Pantazone -D||10 mg domperidone and 40 mg pantoprazole.|
|Ireland||McNeil Healthcare||Motilium||10mg oro-dispersable tablets.|
|Pakistan||Johnson & Johnson Pakistan||Motilium||domperidone 10mg tablets; 30ml suspension.|
|Phillipines||Health Saver Pharma||Abdopen||-|
|Sweden||Ebb medical||Domperidon Ebb (2013)||domperidone 10 mg oro-dispersable and peppermint|
- "Domperidone". Retrieved 2013-06-30.
- Saeb-Parsy K. "Instant pharmacology." John Wiley & Sons, 1999 ISBN 0471976393, 9780471976394 p216.
- Sakamoto Y. et al "Effects of domperidone on gastric emptying: a crossover study using a continuous real-time 13C breath test (BreathID system)." Hepatogastroenterology. 2011 Mar-Apr;58(106):637-41.pmid 21661445.
- Parkman H. P. et al "Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects." Dig Dis Sci. 2011 Jan;56(1):115-24. doi: 10.1007/s10620-010-1472-2. pmid 21063774
- "Domperidone - heart rate and rhythm disorders." Canadian adverse reactions newsletter. Government of Canada. January 2007 17(1)
- Swann IL, Thompson EN, Qureshi K (November 1979). "Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting". British Medical Journal 2 (6199): 1188. doi:10.1136/bmj.2.6199.1188. PMC 1597274. PMID 519355.
- Worthington I. et al "Canadian Headache Society Guideline: acute drug therapy for migraine headache." Can J Neurol Sci. 2013 Sep;40(5 Suppl 3):S1-S80. PMID: 23968886
- Stevens J. E. et al "Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives." Expert Opin Pharmacother. 2013 Jun;14(9):1171-86. doi: 10.1517/14656566.2013.795948.PMID: 23663133.
- Silvers D, Kipnes M, Broadstone V, et al. (1998). "Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group". Clinical therapeutics 20 (3): 438–53. doi:10.1016/S0149-2918(98)80054-4. PMID 9663360.
- Janssen P. et al "The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis." Am J Gastroenterol. 2013 Sep;108(9):1382-91. doi: 10.1038/ajg.2013.118. PMID: 24005344.
- Shindler J. S. et al "Domperidone and levodopa in Parkinson's disease." British Journal of Clinical Pharmacology 18(6) p959-962 December 1984 pmid 6529536 pmc1463696
- Nishikawa N. et al "Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease." Clin Neuropharmacol. 2012 Jul-Aug;35(4):182-4. doi: 10.1097/WNF.0b013e3182575cdb. PMID: 22751085.
- Lertxundi U. "Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?" Curr Drug Saf. 2013 Feb;8(1):63-8. pmid 23656449. Accessed at Pubmed 11 February 2014.
- Malek N. M. "Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease." Parkinsonism Relat Disord. 2013 Jun;19(6):586-9. doi: 10.1016/j.parkreldis.2013.02.004. pmid 23522959.
- Xiao M. "Influence of hippophae rhamnoides on two appetite factors, gastric emptying and metabolic parameters, in children with functional dyspepsia." Hell J Nucl Med. 2013 Jan-Apr;16(1):38-43. doi: 10.1967/s002449910070. pmid 23529392.
- Huang X. et al "Itopride therapy for functional dyspepsia: a meta-analysis." World J Gastroenterol. 2012 Dec 28;18(48):7371-7. doi: 10.3748/wjg.v18.i48.7371. pmid 23326147 PMCID PMC3544044
- Grzeskowiak L. E. et al "Audit of domperidone use as a galactogogue at an Australian tertiary teaching hospital." J Hum Lact. 2013 Feb;29(1):32-7. doi: 10.1177/0890334412459804. PMID: 23015150.
- Donovan T. J. "Medications for increasing milk supply in mothers expressing breastmilk for their preterm hospitalised infants." Cochrane Database Syst Rev. 2012 Mar 14;3:CD005544. doi: 10.1002/14651858.CD005544.pub2. PMID: 22419310.
- da Silva O. P. "Domperidone for lactating women." Canadian Medical Association Journal 28 September 2004 171(7) p725-6 Accessed 30 June 2013.
- "FDA warns against women using unapproved drug, domperidone to increase milk production." U.S. Food and Drug Administration 7 June 2004.
- Asztalos E. V. "Enhancing breast milk production with Domperidone in mothers of preterm neonates (EMPOWER trial)." BMC Pregnancy Childbirth. 31 August 2012 12(87). doi: 10.1186/1471-2393-12-87. pmid 22935052 PMCID: PMC3532128.
- van Noord C. et al "Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands." Drug Saf. 2010 Nov 1;33(11):1003-14. doi: 10.2165/11536840-000000000-00000. PMID: 20925438
- Johannes C. B. et al "Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study." Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):881-8. doi: 10.1002/pds.2016. pmid 20652862.
- Djeddi D. et al "Effect of domperidone on QT interval in neonates." Journal of Pediatrics. 2008 153(5) p596-598. pmid 18589449 doi10.1016/j.jpeds.2008.05.013.
- Gunlemez A. et al "Effect of domperidone on the QTc interval in premature infants." J Perinatol. 2010 Jan;30(1):50-3. doi: 10.1038/jp.2009.96. pmid 19626027.
- Coulthard M. G. and Haycock G. B. [ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1128889/ "Distinguishing between salt poisoning and hypernatraemic dehydration in children."] BMJ 18 January 2003 326(7381) p157-160 Accessed 11 February 2014.
- Yoshizato T. et al "Itraconazole and domperidone: a placebo-controlled drug interaction study." Eur J Clin Pharmacol. 2012 Sep;68(9):1287-94. doi: 10.1007/s00228-012-1258-x. PMID 22418831.
- Boyce M. J. et al " Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study." Br J Clin Pharmacol. 2012 Mar;73(3):411-21. doi: 10.1111/j.1365-2125.2011.04093.x. PMID: 21883386 PMCID: PMC3370345.
- Ung D. et al "Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis." Xenobiotica. 2009 Oct;39(10):749-56. doi: 10.1080/00498250903096121. pmid 19575604
- Swannick G. (ed.) "MIMS Australia." December 2013
- "De Standaard: "Motilium from now on only with prescription"". standaard.be. 2013-05-07. Retrieved 2013-10-03.
- "ipcalabs.com". ipcalabs.com. Retrieved 2013-06-30.
- "torrentpharma.com". torrentpharma.com. Retrieved 2013-06-30.
- GPDA letter to the FDA about domperidone for gastroparesis.
- U.S. National Library of Medicine: Drug Information Portal - Domperidone